A critical appraisal of treatment decisions in multiple sclerosisĝ€"old versus new

Bernd C. Kieseier, Olaf Stüve

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Interferon β 2 and glatiramer acetate have been available for the treatment of multiple sclerosis (MS) for over a decade and their efficacy and safety are well established. These agents have detectable effects on the immune system, but have not been associated with a breakdown of immune surveillance. Novel MS therapies have been approved, or are awaiting approval, that differ from established immunotherapies with regard to their mechanisms of action, modes of administration, adverse-effect profiles and, possibly, the clinical and paraclinical benefits that they may provide for patients. Neurologists will soon be required to make complex treatment decisions with their patients on the basis of very limited clinical data and evidence. Under these circumstances, optimal assessment of risks and benefits will be challenging. In this Review, the anticipated benefits of novel therapies, including reduction in disease activity, possible prevention of disability, and improvement in quality of life, are outlined. In addition, the current acceptance of potential risks-including serious or even life-threatening adverse effects, the likelihood of which may rise with increased cumulative exposure to a particular agent-by patients with MS will be reviewed.

Original languageEnglish (US)
Pages (from-to)255-262
Number of pages8
JournalNature Reviews Neurology
Volume7
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Multiple Sclerosis
Proxy
Therapeutics
Immunotherapy
Interferons
Immune System
Quality of Life
Safety

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

A critical appraisal of treatment decisions in multiple sclerosisĝ€"old versus new. / Kieseier, Bernd C.; Stüve, Olaf.

In: Nature Reviews Neurology, Vol. 7, No. 5, 05.2011, p. 255-262.

Research output: Contribution to journalArticle

@article{49d5806c509d4a919adad491d8948652,
title = "A critical appraisal of treatment decisions in multiple sclerosisĝ€{"}old versus new",
abstract = "Interferon β 2 and glatiramer acetate have been available for the treatment of multiple sclerosis (MS) for over a decade and their efficacy and safety are well established. These agents have detectable effects on the immune system, but have not been associated with a breakdown of immune surveillance. Novel MS therapies have been approved, or are awaiting approval, that differ from established immunotherapies with regard to their mechanisms of action, modes of administration, adverse-effect profiles and, possibly, the clinical and paraclinical benefits that they may provide for patients. Neurologists will soon be required to make complex treatment decisions with their patients on the basis of very limited clinical data and evidence. Under these circumstances, optimal assessment of risks and benefits will be challenging. In this Review, the anticipated benefits of novel therapies, including reduction in disease activity, possible prevention of disability, and improvement in quality of life, are outlined. In addition, the current acceptance of potential risks-including serious or even life-threatening adverse effects, the likelihood of which may rise with increased cumulative exposure to a particular agent-by patients with MS will be reviewed.",
author = "Kieseier, {Bernd C.} and Olaf St{\"u}ve",
year = "2011",
month = "5",
doi = "10.1038/nrneurol.2011.41",
language = "English (US)",
volume = "7",
pages = "255--262",
journal = "Nature Reviews Neurology",
issn = "1759-4758",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - A critical appraisal of treatment decisions in multiple sclerosisĝ€"old versus new

AU - Kieseier, Bernd C.

AU - Stüve, Olaf

PY - 2011/5

Y1 - 2011/5

N2 - Interferon β 2 and glatiramer acetate have been available for the treatment of multiple sclerosis (MS) for over a decade and their efficacy and safety are well established. These agents have detectable effects on the immune system, but have not been associated with a breakdown of immune surveillance. Novel MS therapies have been approved, or are awaiting approval, that differ from established immunotherapies with regard to their mechanisms of action, modes of administration, adverse-effect profiles and, possibly, the clinical and paraclinical benefits that they may provide for patients. Neurologists will soon be required to make complex treatment decisions with their patients on the basis of very limited clinical data and evidence. Under these circumstances, optimal assessment of risks and benefits will be challenging. In this Review, the anticipated benefits of novel therapies, including reduction in disease activity, possible prevention of disability, and improvement in quality of life, are outlined. In addition, the current acceptance of potential risks-including serious or even life-threatening adverse effects, the likelihood of which may rise with increased cumulative exposure to a particular agent-by patients with MS will be reviewed.

AB - Interferon β 2 and glatiramer acetate have been available for the treatment of multiple sclerosis (MS) for over a decade and their efficacy and safety are well established. These agents have detectable effects on the immune system, but have not been associated with a breakdown of immune surveillance. Novel MS therapies have been approved, or are awaiting approval, that differ from established immunotherapies with regard to their mechanisms of action, modes of administration, adverse-effect profiles and, possibly, the clinical and paraclinical benefits that they may provide for patients. Neurologists will soon be required to make complex treatment decisions with their patients on the basis of very limited clinical data and evidence. Under these circumstances, optimal assessment of risks and benefits will be challenging. In this Review, the anticipated benefits of novel therapies, including reduction in disease activity, possible prevention of disability, and improvement in quality of life, are outlined. In addition, the current acceptance of potential risks-including serious or even life-threatening adverse effects, the likelihood of which may rise with increased cumulative exposure to a particular agent-by patients with MS will be reviewed.

UR - http://www.scopus.com/inward/record.url?scp=79955803328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955803328&partnerID=8YFLogxK

U2 - 10.1038/nrneurol.2011.41

DO - 10.1038/nrneurol.2011.41

M3 - Article

C2 - 21467994

AN - SCOPUS:79955803328

VL - 7

SP - 255

EP - 262

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

SN - 1759-4758

IS - 5

ER -